Impurity Profile: A description of the identified and unidentified impurities
present in a new drug substance.
|
Potential Impurity: An impurity
that theoretically can arise during manufacture or storage. It may or may not
actually appear in the new drug substance.
|
Enantiomeric Impurity: A compound with the same molecular formula as the drug
substance that differs in the spatial arrangement of atoms within the
molecule and is a non-superimposable mirror image.
|
Identified Impurity: An impurity for
which a structural characterisation has been achieved.
|
Unidentified Impurity: An impurity for which a structural characterisation has
not been achieved and that is defined solely by qualitative analytical
properties (e.g., chromatographic retention time).
|
Specified Impurity: An impurity
that is individually listed and limited with a specific acceptance criterion
in the new drug substance specification. A specified impurity can be either
identified or unidentified.
|
Unspecified impurity: An impurity that is limited by a general acceptance
criterion, but not individually listed with its own specific acceptance
criterion, in the new drug substance specification.
|
Pharma treasures is an informatory site, which shares pharma related articles. The ultimate goal of this site is to become a knowledge hub by gathering all pharma related technical information under one roof...... This blog mainly talks about QMS,cGMP,Regulatory Filings & Guidelines,Validation & Qualifications,Drug Stability,FDA 483s &Media Fill. Hope this blog will cater the needs of both fresher’s and experienced professionals.
Very simply explained keep the good work
ReplyDelete